SCHEMBL7498482

SCHEMBL7498482

Cc1nc2cnccc2n1Cc1ccc(N)cc1

nearest known ligand 0.53

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 2/20 0.50
NR2F2 P24468 2/20 0.50
TNF P01375 1/20 0.50
RAB9A P51151 1/20 0.50
PTAFR P25105 2/20 0.48
RPS6KA5 O75582 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9049974 0.89 GALR3 (0.50) GALR3NR2F2TNFRAB9APTAFR
Bromide SCHEMBL9054549 0.87 GALR3 (0.49) GALR3NR2F2TNFRAB9APTAFR
SCHEMBL9051522 0.86 GALR3 (0.52) GALR3NR2F2TNFRAB9APTAFR
SCHEMBL9051695 0.86 GALR3 (0.50) GALR3NR2F2TNFRAB9APTAFR
SCHEMBL7497522 0.86 GALR3 (0.68) GALR3NR2F2TNFRAB9APTAFR
Bromide SCHEMBL9052476 0.84 GALR3 (0.51) GALR3NR2F2TNFRAB9APTAFR
SCHEMBL9057251 0.83 PTAFR (0.48) GALR3NR2F2TNFRAB9APTAFR
SCHEMBL9051019 0.83 PTAFR (0.49) GALR3NR2F2TNFRAB9APTAFR
SCHEMBL7494477 0.83 GALR3 (0.48) GALR3NR2F2TNFRAB9APTAFR
SCHEMBL8324796 0.83 PTAFR (0.56) PTAFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734386-B1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES ABBOTT LAB (US) 2002-02-06 EP disclosed
EP-0734386-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES Abbott Laboratories (US) 1996-10-02 EP disclosed
US-5486525-A ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1996-01-23 US disclosed
WO-1995016687-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES ABBOTT LABORATORIES (US) 1995-06-22 WO disclosed